From: Role and research progress of hematological markers in laryngeal squamous cell carcinoma
Year | Author | Case | Object | Nutritional markers | Cut-off value | Conclusion |
---|---|---|---|---|---|---|
2001 | Nguyen-Tan et al. [128] | 223 | T3-4 LSCC | HB | HB: 12.5 g/dL | HB levels > or = 12.5 g/dL during radiotherapy was a favorable prognostic factor for OS |
2004 | Haugen et al. [129] | 214 | stage I-IV LC | HB | HB: 137.5Â g/L | Preradiotherapy HB level, predicts locoregional control and survival in patients with LC treated with radiotherapy |
2012 | Zeng et al. [130] | 57 | locoregionally advanced LC treated with chemoradiotherapy | CRP | CRP: 8Â mg/L | The elevation of CRP before treatment predicts a poor prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy |
2017 | Chen et al. [131] | 241 | LSCC | AGR | AGR: 1.28 | Low preoperative AGR could serve as a valuable and easily assessed blood-based indicator to predict the prognosis of LSCC patients |
2017 | Yu et al. [132] | 129 | LSCC | CAR | CAR: 0.047 | Pretreatment CAR may be a significant prognostic marker in LSCC |
2019 | Zhou et al. [133] | 232 | LSCC | AGR | AGR: 1.31 | AGR might be a promising marker to better predicting prognosis of LSCC patients |
2019 | Kuboki et al. [134] | 56 | Underwent total laryngectomy or total pharyngolaryngectomy | CAR | CAR: 0.32 | CAR may be a novel and useful indicator for predicting postoperative outcomes in patients with hypopharyngeal and laryngeal cancer |
2019 | Fu et al. [135] | 61 | LC patients received radiotherapy | CRP | CRP: 10Â mg/L | CRP may be used as a prognostic indicator for laryngeal cancer patients treated with radiotherapy |
2020 | Gorphe et al. [50] | 68 | T3 LC treated with induction chemotherapy using a preservation protocol | HB | - | In LC, patients treated with a preservation protocol, anemia before induction chemotherapy was associated with shorter survival, independently of the response to chemotherapy |
2020 | Sahin et al. [136] | 432 | Underwent laryngeal microsurgery because of benign and premalignant lesions or malignancy | CRP | - | CRP was shown to be increased in patients with laryngeal malignancies |
2021 | Tanoue et al. [125] | 46 | R/MÂ HNSCCÂ treated with nivolumab | CAR | CAR: 0.30 | pretreatment CAR was an independent marker of survival and efficacy of nivolumab in recurrent or metastatic HNSCC patients, and that the CAR was a better predictor than the NLR |